J.F. Dufour

Discipline

Psychologie (1) Economies et finances (1)

Type de document

Articles (12)

Co-auteur

Date

Source

Mot-clé

Treatment (9) Patients (9) Patients (9) Human beings (7) Liver (7) thérapie (6) Ci (Chinese poetry) (6) Therapeutics (6) maladie (6) risque (5) infection (5) maladie (5) Risk (5) Infection (5) Hepatitis C (5) cohorte (5) association (4) âge (4) adulte (4) Swiss (4) Social groups (4) Serum (4) Ribavirin (4) Management (4) Liver--Cancer (4) Cancer (4) Older people (4) Age (4) Fibrosis (4) Age (4)

Documents écrit par J.F. Dufour (12) | parle de J.F. Dufour (0)

The current and future burden of hepatitis B in Switzerland: a modelling study.
F. Negro et al. (5 juin 2023)
Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis.
M. Correia de Sousa et al. (4 oct. 2021)
COVID-19 in an international European liver transplant recipient cohort.
C. Becchetti et al.
Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients.
L. Quteineh et al.
Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis.
S. Beckebaum et al. (13 nov. 2018)
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation.
L. Quteineh et al.
Separation of small metabolites and lipids in spectra from biopsies by diffusion-weighted HR-MAS NMR: a feasibility study.
G. Diserens et al. (2014)
Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development.
C.M. Lange et al. (2013)
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
E. Patin et al.
A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C.
C.M. Lange et al. (2012)
Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland.
K. Overbeck et al. (2010)
Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C.
B.S. August-Jörg et al. (23 août 2003)